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CT1
MINIMAL INITIAL CHEMOTHERAPY PLUS INVOLVED FIELD 
RADIOTHERAPY (RT) VERSUS MANTLE FIELD RT FOR 
CLINICAL STAGE IA/IIA SUPRA-DIAPHRAGMATIC
HODGKIN’S DISEASE (HD). RESULTS OF THE UK
LYMPHOMA GROUP LY07 TRIAL.
Radford JA1, Williams MV2, Hancock BW3, Hoskin P4, Sun-Mynt H5, 
Smith P6, Qian W6 and Linch D7 on behalf of all LY07 collaborators.
1Christie Hospital, Manchester, 2Addenbrookes Hospital, Cambridge, 
3Weston Park Hospital, Shefﬁ  eld, 4Mount Vernon Hospital, Northwood, 
5Clatterbridge Hospital, Wirral, 6Cancer Research UK and University 
College Trials Centre and 7University College Hospital, London.
Between November 1996 and June 2001, 226 pts with clinical stage 
I/II supra-diaphragmatic HD (no B symptoms or mediastinal bulk) were 
randomised to receive either mantle ﬁ  eld RT (arm A, n=115) or 4 wks 
of VAPEC-B chemotherapy (doxorubicin 35mg/m² iv at wks 1 and 3, 
cyclophosphamide 350mg/m² iv at wk 1, etoposide 100mg/m² po days 1-5 
at wk 3, vincristine 1.4mg/m² iv at wks 2 and 4 and bleomycin 10,000 IU/m² 
iv at wks 2 and 4 with prednisolone 50mg daily for 4 wks and prophylactic 
cotrimoxazole/ketoconazole) followed by involved ﬁ  eld RT (arm B, n=111). 
In both arms RT dose was 30-40 Gy in daily fractions of 1.8-2 Gy. 
At completion of treatment CR/CRu had been achieved by 91% pts in arm A 
and 90% in arm B, and PR by 7% in arm A and 9% in arm B. After a median 
follow-up of 51 months (range 0-85 months), 5 year relapse-free survival is 
70% in arm A and 87% in arm B (p=0.002) and 5 year survival is 92% in arm 
A and 98% in arm B (p=0.036).
This analysis of the LY07 trial shows that 4 wks of VAPEC-B chemotherapy 
followed by involved ﬁ  eld RT is superior to mantle ﬁ  eld RT alone in early 
stage HD. These results are similar to those from an earlier pilot study in 
which mantle ﬁ  eld RT was employed in both arms of the trial for pts with 
mediastinal involvement (abstract 070, 8th International Conference on 
Malignant Lymphoma, Lugano, 12-15 June 2002) and suggest that wide-
ﬁ  eld RT can be avoided in this group of pts by incorporating minimal initial 
chemotherapy into the treatment programme.
CT2
RANDOMISED CONTROLLED TRIAL OF ABVD VS. TWO 
MULTI-DRUG REGIMENS (MDRS) FOR ADVANCED HODGKIN’S 
LYMPHOMA (HL): INITIAL RESULTS OF UKLG LY09 
(ISRCTN97144519).
B Hancock1, J Radford2, MH Cullen3, J Walewski4, MR Sydes5, 
D Ryder2, P Smith6, S Clawson5, SP Stenning5, PM Johnson7.
1Weston Park Hospital, Shefﬁ  eld, UK; 2Christie Hospital, Manchester, 
UK; 3Queen Elizabeth Hospital, Birmingham, UK; 4 MSCM Cancer 
Centre, Warsaw, Poland; 5MRC Clinical Trials Unit, London, UK; 
7BNLI, Cancer Research UK Clinical Trials Centre, London, UK; 7 
Southampton General Hospital UK.
Background: This UKLG trial compared ABVD with two MDRs for
treating advanced HL in terms of progression-free survival (PFS) and overall
survival (OS).  Methods: Patients with advanced (stage IIAX-IV) HL were
randomised between standard ABVD (C) and each clinician’s choice of two
MDRs: Alternating ChlVPP/PABlOE (Alt) or Hybrid ChlVPP/EVA (Hyb).
Six cycles were planned, plus two extra for slow responders, with guidance
on radiotherapy (RT). MDR choice was speciﬁ  ed at randomisation: patients
(pts) were effectively randomised between CAlt and Alt or between CH and
Hyb.  Results: 807 pts were randomised Apr97 - Sept01; 406 allocated
ABVD and 401 MDRs. The groups were well-balanced; 42% female, mean
age 37 years, 36% IPI score 0-1. At 3yr median follow-up, 191 PFS events
are reported. For the primary C vs MDRs comparison, the PFS hazard ratio
(HR) = 1.00, 95% CI (0.76, 1.34), p=0.99 (HR > 1.0 favours C) with some
evidence of heterogeneity according to choice of MDRs (2 interaction test,
adjusting for IPI score, p=0.05). The survival HR = 1.25 (0.82, 1.90), p=0.33
with no clear evidence of heterogeneity according to choice of MDR (χ2
p=0.61).  Conclusion: No clear evidence of a difference between ABVD
and the MDRs was demonstrated with respect to PFS and OS, although
preliminary analysis suggests the two MDRs may differ in efﬁ  cacy. A centre
effect was evident in the duration of chemotherapy and use of G-CSF and
radiotherapy: this was related to the pre-randomisation choice of MDR but
was balanced across the allocated treatment arms.
CT3
RESULTS FROM THE UK NCRI ADJUVANT BREAST CANCER 
(ABC) INTERNATIONAL TRIAL: POLYCHEMOTHERAPY 
AND OVARIAN ABLATION IN WOMEN WITH EARLY BREAST 
CANCER PRESCRIBED 5 YEARS TAMOXIFEN.
A M Brunt, JM Bliss, L Johnson, D Lawrence, J Yarnold, on behalf of 
the ABC Trial Management Group.
Background: The ABC trial tested the added beneﬁ   ts of ovarian 
ablation (OA) and/or chemotherapy (CT) in women with early breast 
cancer prescribed tamoxifen (T) 20mg daily for 5 years. Methods: 
Premenopausal women were randomised to OA (any type) vs. no OA 
(elective CT was allowed). Pre- and post-menopausal women in whom 
the added beneﬁ  ts of CT were unclear were randomised to CT (any 
type) vs. no CT (elective OA was allowed in premenopausal women). 
All patients had stage 1-3a breast cancer. Main endpoints: relapse-free 
survival (RFS) and overall survival (OS). Results: 1993 to 2000, 3854 
patients were randomised from 106 UK and 16 non-UK centres. 1991 
(987 CT, 1004 no CT) in the CT comparison; 2144 (1063 OA, 1081 no 
OA) in the OA comparison. CT: CT suggested an improvement in RFS 
(HR 0.86 [95%CI 0.73-1.01] p=0.06) and OS (HR 0.87 [95%CI 0.73-
1.04] p=0.12). Adjusting for nodal status, ER, age and OA suggested a 
slightly increased the magnitude of beneﬁ  t of CT (RFS: HR 0.83 (0.71-
0.97) p=0.024, OS: HR0.84 (0.70-1.00) p=0.051). RFS was independent 
of ER status but not age. OA: With OA, no difference was seen in RFS 
(HR 0.98, 95%CI 0.83-1.16, p=0.81) or OS (HR 0.96, 95%CI 0.79-
1.16, p=0.64), unadjusted, adjusted or in subgroups based on age, nodal 
status, ER status or elective CT. Conclusion: This is the ﬁ  rst study to 
report the added impact of adjuvant CT or OA against a background of 
prolonged (5 years) T. Beneﬁ  t of CT on RFS and OS is retained in this 
context but OA appears to have no additional effect.
CT4
DEVELOPMENT OF BONE METASTASES FROM PROSTATE 
CANCER: FIRST RESULTS OF THE MRC PR04 TRIAL 
(ISCRTN61384873)
Mason MD1 and MRC PR04 collaborators; 1University of Wales 
College of Medicine, Cardiff, UK.
Background: The skeleton is the most common site of metastases from
prostate cancer. Bisphosphonates have been shown to slow development
of metastases from breast cancer and myeloma and to modify pain from
bone metastases from prostate cancer. 
Methods:  Phase III double-blind placebo-controlled randomised
trial of oral bisphosphonate in men receiving standard treatment for
locally advanced PCa with no evidence of bone metastases and WHO
performance status 0-2.  The primary endpoint was time to development
of symptomatic bone metastases or PCa death. Treatment consisted of
either 4 tablets/day oral sodium clodronate (2,080mg Loron 520) (A) or
4 tablets/day of matching placebo control (C). Patients were encouraged
to stay on trial medication for 5 years or until the primary trial endpoint
had been reached. 
Results: Patients: 508 patients were randomised (target 500) over
3.5yrs (Jun94-Dec97): 254A, 254C. Baseline characteristics were well
balanced. All patients have completed their allocated trial medication.
Efﬁ  cacy and toxicity: First results are due for ﬁ  rst analysis in Spring
2004, based on at least 145 deaths with median follow-up of at least
5 years  in surviving patients.  Data will be presented by unblinded
treatment arm in terms of trial medication (time on trial medication and
reason for stopping trial),adverse events (rates of adverse events and
dose-modifying adverse events, progression-free and overall survival
(with numbers of events, log-rank test of treatment effect, median time
to events, KM plots of time to events). Conclusion: The results will
be considered in the context of sister trial, PR05, in metastatic disease
which were published in JNCI in September 2003.  
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RANDOMISED TRIAL OF HIGH DOSE RAPID SCHEDULE WITH 
CONVENTIONAL SCHEDULE FOR STAGE 4 NEUROBLASTOMA 
OVER THE AGE OF ONE YEAR
Pearson ADJ, Pinkerton CR, Lewis I, Imeson J, Ellershaw C, Machin D
on behalf of the European Neuroblastoma Study Group and the United 
Kingdom Children’s Cancer Study Group
This trial aimed to test whether increasing the dose intensity of 
induction chemotherapy, by rapid drug scheduling, in stage 4
neuroblastoma over one year will improve event-free survival (EFS).
Eligible patients, were randomised to either COJEC (Rapid) or OPEC/
OJEC (Standard). Each regimen utilised the same total cumulative dose
of cisplatin, carboplatin, etoposide, cyclophosphamide and vincristine,
but the dose intensity (mg/m2/week) with R was 1.8 fold higher. The S
regimen was given every 21 days if there was haematological recovery
while R every 10 days regardless of blood counts. In those patients who
were responding, surgical excision of the primary tumour was attempted 
followed by myeloablative therapy (melphalan at 200 mg/m2) and 
haemopoietic stem cell rescue.
In total 262 patients: 132 S and 130 R were randomised. Of these
76.5% with S and 81.5% with R received at least 90% of the scheduled 
therapy and the relative dose intensity achieved was 1.85. Myleoablative
therapy was delivered at a median of 53 days earlier with R. Apart from
ototoxicity, the toxicity was tended to be greater with R. The 3 and 5
year EFS were 30.8% and 30%, respectively with R, compared to 24.2%
and 18% with S.
In conclusion dose intensity can be increased in high-risk neuroblastoma,
but there is little advantage in EFS and OS in the ﬁ  rst two years after 
treatment. Beyond this time there is a suggestion of better outcome.
The rapid induction regimen, COJEC, allows myeloablative intensity
therapy to be given much earlier, which could contribute to outcome.
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